


Cancer cell survival

Gui et al., In revision
 Patiño et al., eBioMedicine 2024
 Cazzoli et al., Cell Reports 2023



Metastasis


Elgendy et al., Nature Comm. 2014

Cancer Metabolism



Anti-cancer drug resistance

Elgendy et al., Cancer Cell 2019 (Corresponding author)
 Elgendy et al., IJC 2019
 Elgendy et al., JCI 2017 (Corresponding author)
 Pallavi et al., Nature Comm. 2024




Cancer immunotherapy



Dynamic, international, and friendly group

Come join us






Background

Acute myeloid leukemia (AML) is a cancer that begins in the bone marrow. AML involves the uncontrolled growth of abnormal myeloid cells, which disrupts the formation of normal blood cells. A key area of recent investigation is the metabolic cross-talk between immune and AML cells. Better understanding of this crosstalk will allow the development of metabolic approaches for therapy in AML.

AIM OF THE PROJECT


The project aims to examine the metabolic crosstalk between metabolically distinct AML cells and immune T cells using high-throughput omics-based approach. A comprehensive evaluation of the cross-talk will provide in-depth analysis of the mechanisms by which immune evasion takes place and how such alterations could be targeted to improve anti-tumor immune response.

Could be YOU



Co-culture assays with cytotoxic T cells

Could also be you, fighting AML with T cells



Metabolic interventions and functional analyses :
 -Cell proliferation & apoptosis assays
 -Protein expression and enzymatic activity
 -Redox homeostasis
 -Signaling pathways

Why this project now?



NOVELTY

ERC Funded Project



TECHNIQUES

Wide range of cutting edge as well as general molecular techniques



TRANSLATION

-Tailored strategies targeting tumor metabolism.